Oral Contraceptive Containing Chlormadinone Acetate and Ethinylestradiol Reduces Plasma Concentrations of Matrix Metalloproteinase-2 in Women with Polycystic Ovary Syndrome


Autoria(s): Gomes, Valeria A.; Vieira, Carolina S.; Jacob-Ferreira, Anna L.; Belo, Vanessa A.; Soares, Gustavo M.; Franca, Janaina B.; Ferriani, Rui A.; Tanus-Santos, Jose E.
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

12/10/2013

12/10/2013

2012

Resumo

Biochemical markers of cardiovascular disease, including matrix metalloproteinases (MMPs), are altered in women with polycystic ovary syndrome (PCOS), with many of these alterations thought to be due to excess androgen concentrations. Despite oral contraceptives (OCs) being the first-line pharmacological treatment in women with PCOS and the importance of MMPs in many physiological conditions and pathological states, including cardiovascular diseases, no study has yet evaluated whether OCs alter plasma concentrations of MMPs. We therefore assessed whether treatment with an OC containing the anti-androgenic progestogen alters MMP profiles in women with PCOS. We analysed 20 women with PCOS who wanted hormonal contraception (OC-PCOS group), 20 ovulatory women who required hormonal contraception (OC-control group) and 20 ovulatory women who wanted non-hormonal contraception (non-OC-control group). OC consisted of cyclic use of 2 mg chlormadinone acetate/30 mu g ethinylestradiol for 6 months. Plasma concentrations of MMP-2, MMP-9, TIMP-1 and TIMP-2 were measured by gelatin zymography or enzyme-linked immunoassays. OC treatment for 6 months significantly reduced plasma MMP-2 concentrations in the OC-control and OC-PCOS groups and TIMP-2 and TIMP-1 concentrations levels in the OC-control group (all p < 0.05), but had no effects on MMP-9 concentrations or on MMP-2/TIMP-2 and MMP-9/TIMP-1 ratios in any group (all p > 0.05). These findings indicated that long-term treatment with an OC containing chlormadinone acetate plus ethinylestradiol reduced plasma MMP-2 concentrations in both healthy and PCOS women. As the latter have imbalances in circulating matrix MMPs, treatment of these women with an OC may be beneficial.

Fundacao de Amparo a Pesquisa do Estado de Sao Paulo

Fundacao de Amparo a Pesquisa do Estado de Sao Paulo

Conselho Nacional de Desenvolvimento Cientifico e Tecnologico

Conselho Nacional de Desenvolvimento Cientifico e Tecnologico

Identificador

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, HOBOKEN, v. 111, n. 3, supl., Part 3, pp. 211-216, SEP, 2012

1742-7835

http://www.producao.usp.br/handle/BDPI/34166

10.1111/j.1742-7843.2012.00895.x

http://dx.doi.org/10.1111/j.1742-7843.2012.00895.x

Idioma(s)

eng

Publicador

WILEY-BLACKWELL

HOBOKEN

Relação

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Direitos

closedAccess

Copyright WILEY-BLACKWELL

Palavras-Chave #PREMATURE CAROTID ATHEROSCLEROSIS #RENOVASCULAR HYPERTENSIVE-RATS #INCREASED CIRCULATING LEVELS #NORMAL-WEIGHT WOMEN #MATRIX-METALLOPROTEINASE-9 ACTIVITY #MYOCARDIAL-INFARCTION #VASCULAR DYSFUNCTION #METABOLIC SYNDROME #MMP-2 EXPRESSION #PROSTATE-CANCER #PHARMACOLOGY & PHARMACY #TOXICOLOGY
Tipo

article

original article

publishedVersion